Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD BRANFORD, Conn., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel...

Thetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease BRANFORD, Conn., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD),...